Viscum Album vs Chemotherapy – A Holistic Approach to Cancer Care | ABNOBA India
Explore the benefits of Viscum album (mistletoe extract) as a complementary therapy to chemotherapy. Learn how ABNOBA India's natural solutions support cancer treatment with improved well-being and reduced side effects.

Cancer treatment has long been dominated by chemotherapy—a powerful tool that targets and kills rapidly dividing cancer cells. However, chemotherapy is often accompanied by intense side effects, including nausea, hair loss, fatigue, and weakened immunity. While effective, these downsides have prompted many patients and healthcare providers to explore supportive or complementary therapies like Viscum album.

Viscum album, commonly known as European  mistletoe, is a plant-based extract developed under strict research protocols by ABNOBA GmbH in Germany. ABNOBA India brings these pharmaceutical-grade mistletoe products to Indian patients, offering them access to a natural and integrative option.

Unlike chemotherapy, which aggressively attacks cancer cells, Viscum album works by stimulating the immune system, promoting natural cell death (apoptosis) in tumor cells, and improving overall vitality. Patients using mistletoe therapy often report better quality of life, reduced fatigue, and improved emotional well-being—even when undergoing chemotherapy.

Rather than replacing chemotherapy, Viscum album is typically used alongside it. Clinical studies have shown that this combination can enhance patient tolerance to chemotherapy, reduce side effects, and potentially improve treatment outcomes. It is a holistic strategy that aligns well with integrative oncology, where the goal is not just to fight cancer but also to support the patient’s entire body and mind.

 

In conclusion, Viscum album is not a substitute for chemotherapy but a scientifically backed complementary therapy. Always consult your oncologist or a trained integrative medicine professional to determine the best approach for your individual case.

disclaimer

What's your reaction?